October 23, 2018
The Global Alliance for Genomics and Health (GA4GH) held its 6th Plenary Meeting in Basel, Switzerland earlier this month. The meeting brought together more than 430 participants from 25 countries, making it the biggest GA4GH event yet. Attendees of the meeting learned about GA4GH Connect – a strategic phase focused on connecting GA4GH development work to the immediate data sharing needs of the community.
At the meeting, Peter Goodhand, Chief Executive Officer of GA4GH, announced a call for new real-world genomic data initiatives – Driver Projects – with a specific focus on global collaboration and scientific merit. The Steering Committee will announce the accepted Driver Projects in February 2019.
Also at the meeting, Dr. Marc Fiume, Chief Executive Officer of DNAstack and OICR Associate, presented on the recent progress of the Beacon Project – an international collaborative initiative that has developed a realtime discovery platform for genetic mutations. The Beacon Project has released Beacon API V1.0.0 on Friday – the first genomic data interoperability standard from the GA4GH 2018 Strategic Roadmap.
“It was a fantastic meeting and an eye-opening experience to learn about how the field of precision medicine is linking genomic tools with clinical databases and patient outcomes to drive a patient-centered, learning healthcare model,” says Dr. Laszlo Radvanyi, President and Scientific Director of OICR. “GA4GH continues to play a critical role in establishing standards for genomic data acquisition, quality, interpretation, integrity, security, and sharing that many national genomic health initiatives are beginning to embrace around the world.”
May 1, 2018
Ontario Institute for Cancer Research welcomes new President and Scientific Director, Dr. Laszlo Radvanyi
Toronto (May 1, 2018) – Mr. Tom Closson, Chair of the Ontario Institute for Cancer Research’s (OICR) Board of Directors, today welcomed to the Institute Dr. Laszlo Radvanyi, OICR’s new President and Scientific Director. Radvanyi was selected after an extensive international search and has extensive oncology-related experience from his time spent in industry, with a particular focus in immuno-oncology. Radvanyi will work with the Ontario cancer research community, and OICR’s commercialization partner FACIT, to see that Ontario’s best innovations are reaching cancer patients as quickly as possible.
Radvanyi joins OICR from EMD Serono (Merck KGaA, Darmstadt Germany), where he was a Senior Vice President, Global Senior Scientific Advisor in Immunology and Immuno-Oncology. There he played a central scientific advisory role, facilitating major academic centre alliances and ran EMD Serono’s CAR T-cell program, in partnership with Intrexon. He also served as Global Head of the Immuno-Oncology Translational Innovation Platform, where he was instrumental in rebuilding immuno-oncology research at the company, hiring new world-class scientific staff, as well as pruning and re-orienting the discovery pipeline.
February 9, 2018
The Global Alliance for Genomics and Health (GA4GH) has laid out its plans for the next five years as it continues to align its activities with meeting the key needs of the genomics data community. The Strategic Roadmap encompasses the standards and frameworks that will be developed by GA4GH and will be updated with new deliverables annually. OICR is a GA4GH Host Institution.
August 9, 2017
A newly published paper in Genetics in Medicine has reinforced the fundamental importance of collecting information about genetic variances in a single large database. With so much important genetic information being used globally to understand the underlying genetic influences of diseases, researchers and clinicians need an accessible repository to share this information.
May 8, 2017
OICR is pleased to announce that Mr. Peter Goodhand is OICR’s new President for a one-year term. Goodhand served as Interim President of OICR over the past 10 months, in addition to his role as Executive Director of the Global Alliance for Genomics and Health (GA4GH). We spoke to Goodhand about why he took on the new, expanded job, how it differs from his previous role, what this means for the search for a permanent OICR President and Scientific Director and what he’s planning for the next year at OICR.
February 23, 2017
Financing leverages and strengthens Ontario’s next-generation radiotherapeutics expertise, products
TORONTO, ON (February 23, 2017) – The Fight Against Cancer Innovation Trust (FACIT) and the Ontario Institute for Cancer Research (OICR) are pleased to report that Fusion Pharmaceuticals Inc. (Fusion) has closed a US$25M Series A financing, with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as the lead investor. Additional, new investors include venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well as founding investor FACIT.
September 27, 2016
We are pleased to share with you the 2015-16 annual report for the Ontario Institute for Cancer Research (OICR).
This year’s report describes the world-class research currently underway at the Institute and details our efforts to bring the fruits of this research to patients in partnership with the Fight Against Cancer Innovation Trust. From new techniques to probe cancer genomes to new partnerships for sharing cancer data securely via the cloud, OICR’s innovations have an impact across the province and around the world.
This report also looks forward to our next five years, as we embark on our new Strategic Plan for 2016-2021. We are confident this new plan will lead to continued research success in the future.
Today OICR’s research supports more than 1,700 investigators, clinician scientists, research staff and trainees across the province of Ontario. These researchers, working with collaborators provincially, nationally and internationally, are making a real impact in the fight against cancer.
We hope you enjoy reading about their work. We welcome any feedback you may have at email@example.com.
Mr. Peter Goodhand
Dr. Lincoln Stein
Interim Scientific Director
August 17, 2016
Toronto (August 17, 2016) – Mr. Peter Goodhand, President of The Ontario Institute for Cancer Research (OICR), today announced a new collaborative research study in partnership with Thermo Fisher Scientific and Queen’s University to help bring more targeted diagnosis and treatment to breast cancer patients in the future.
June 9, 2016
TORONTO, CANADA (June 9, 2016) — In today’s Science, the Global Alliance for Genomics and Health (GA4GH) calls for a federated data ecosystem for sharing genomic and clinical data. The authorship, which includes Canadian leaders as well as a diverse team of international leaders in academia, research, medicine, and industry, argues that a common framework of principles, protocols, and interoperable technical systems are necessary to enable responsible and effective data sharing.